As one of the largest children’s hospitals in Europe, Alder Hey is the perfect place to deliver the highest quality research.
Our aim is to become a world class centre for research, innovation and education and our reputation for paediatric research has improved significantly over the last few years. Key areas of excellence have emerged within pharmacology, infection, oncology, inflammation, infection and international child health.
Throughout our long history we have remained at the forefront for children’s health research, leading the field for drug safety. Alder Hey was a founding partner of the NIHR Medicines for Children Research Network and is now the base for its successor, the NIHR Clinical Research Network for Children.
Find out more about the NIHR Alder Hey Clinical Research Facility by clicking here.
Alder Hey is very proud to have enrolled over 41,000 children and young people into research studies, more than any other children’s healthcare provider in the UK. At any time, there are over 100 clinical research studies taking place at Alder Hey; ranging from observational studies to complex, international trials supported by the NIHR Clinical Research Facility. Our CRF provides a dedicated environment for leading edge research, enabling Alder Hey to develop safe studies of complex paediatric medicines and interventions.
During 2017/18, over 9,000 children and young people were enrolled into clinical research studies, placing Alder Hey within the top 3% of NHS organisations with respect to research volume.
Our thriving research portfolio is delivered in partnership with a number of NHS, academic and commercial partners. Our academic partners include the University of Liverpool, Liverpool John Moores University, University of Central Lancashire, Lancaster University and Edge Hill University. Alder Hey is also a member of Liverpool Health Partners and has collaborations in the UK and internationally with a large number of healthcare institutions, universities and commercial organisations.
Several of our staff hold contracts with partner academic institutions ensuring that our research remains relevant and meaningful for children, families and healthcare professionals.
Meet the team
Director of Research
Professor Matthew Peak: firstname.lastname@example.org | 0151 252 5570
Associate Chief Operating Officer for Research
Dr Charlie Orton: email@example.com
Research Business Unit Clinical Lead
Dr Jo Blair: firstname.lastname@example.org | 0151 252 5570
NIHR Alder Hey Clinical Research Facility Manager
Gaurika Kapoor: email@example.com | 0151 252 5570
Research Governance & Quality Assurance Lead
Lucy Cooper: firstname.lastname@example.org | 0151 252 5570
Clinical Director of NIHR Alder Hey Clinical Research Facility
Professor Michael Beresford: email@example.com | 0151 252 5693
Richard Kirk: firstname.lastname@example.org | 0151 252 5570
Senior Research Nurse
Teresa Moorcroft: email@example.com
Portfolio and Performance Coordinator
Edward Staunton: Edward.Staunton@alderhey.nhs.uk | 0151 252 5570
Team Personal Assistant
Rebecca Murphy: firstname.lastname@example.org | 0151 252 5570
Research Finance Assistants
Charles Otim: Charles.Otim@alderhey.nhs.uk | 0151 252 5570
Our performance data
Alder Hey runs a lot of research studies and often children and families are asked to take part. During 2016/17, over 5,000 children and young people were enrolled into clinical research studies. As part of our commitment to excellent research, we initiate studies quickly, safely and successfully.
As part of this commitment, our performance statistics are available to download in this report, showing Alder Hey’s performance in initiating research studies and in recruiting patients to studies:
The statistics of initiating studies are based on the number of days it takes a researcher to get approval from the hospital to conduct a study. The national target is 40 days.
The statistics for recruiting patients to studies show the number of days taken to recruit the first patient to a study, once hospital approval has been given. The national target is 30 days.